US · Healthcare · Medical Devices
EPS came in at 0.56 against a street estimate of 0.48 — a beat of 16.7%.
Analysts rate Integra LifeSciences Holdings a hold (3 buy, 6 hold, 2 sell out of 11) with an average price target of $18.38.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.74% |
| Rubric Capital Management LP | 9.97% |
| Amvescap Plc. | 4.82% |
| Vanguard Portfolio Management, LLC | 4.81% |
| Morgan Stanley - Brokerage Accounts | 4.62% |
| Paradigm Capital Management, Inc. | 4.42% |
| Fuller & Thaler Asset Management Inc | 4.42% |
| State Street Corp | 3.79% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Integra LifeSciences announced pricing of $450 million of 9.500% senior secured notes due 2033. • The notes were issued through a | 2026-10-09 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Integra LifeSciences expects third-quarter 2026 reported revenue of $410 million to $412 million. • Revenue includes an estimated | 2026-10-02 |
| Reg FD disclosure · Q3 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics, revenue figures, or earnings data are | 2026-09-08 |
| Quarterly report · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORP - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $810.7 million (2026) vs. $798.3 million (202 | 2026-07-29 |
| Results announced · Q3 2026 INTEGRA LIFESCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenues: $418.8 million, up 0.8% reported / 0.7% organic vs. prior year • | 2026-07-29 |
| Board / officer change · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 7, 2026 • 3,550,000 additional shares approv | 2026-05-08 |
| Quarterly report · Q1 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $391.9 million (vs. $382.7 million in Q1 | 2026-05-05 |
| Board / officer change · Q2 2026 INTEGRA LIFESCIENCES HOLDINGS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Dr. Stuart Essig appointed President and Chief Executive Officer eff | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Integra LifeSciences Holdings — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.